JUPITER NEUROSCIENCES, INC. Annual Report Summary

I’ve put together this guide to help you understand how Jupiter Neurosciences performed. My goal is to explain their complex filings in plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Jupiter Neurosciences is a clinical-stage pharmaceutical company. This means they are currently in the research and testing phase, focusing on treatments for brain-related inflammation. Their lead product, JOTROL™, is a specialized resveratrol formulation currently in Phase IIa trials for Parkinson’s Disease and Friedreich’s Ataxia. Because they are still in the development stage, they have not yet generated revenue from drug sales and rely on outside funding to cover their $4.2 million in annual research costs.

2. Major changes this year

The company has pivoted toward a dual-revenue strategy. In March 2025, they launched Nugevia, a consumer wellness brand that utilizes the same delivery technology as their pharmaceutical pipeline. By late 2025, they transitioned to a direct-to-consumer sales model, leveraging social media to drive traffic to their website. The goal is to generate operational cash flow to offset drug development costs and reduce the need for further equity financing.

3. Financial health: The "Going Concern" warning

It is important to note that the company is in a precarious financial position. Management has issued a "substantial doubt" warning regarding their ability to continue as a going concern. They currently hold approximately $2.1 million in cash, which is insufficient to cover their projected expenses for the coming year. To address this, the company raised $11 million in December 2024 by issuing 2.75 million shares at $4.00 each, though these funds are being depleted to cover debt obligations and ongoing research.

4. Key risks

• Dilution: Future fundraising efforts will likely require the issuance of additional shares, which reduces your ownership percentage in the company.
• Clinical Trial Uncertainty: The company’s valuation is tied almost entirely to the success of JOTROL™. If clinical trials fail or the FDA does not grant approval, the company’s primary asset could lose its value, potentially resulting in a total loss of investment.
• Stock Volatility: Due to a limited number of shares available for trading, the stock price is prone to significant swings based on minor news or shifts in market sentiment.
• Dependency: Jupiter licenses its core technology from Aquanova AG. Should this licensing agreement be terminated, the company would lose the delivery mechanism essential to its entire drug pipeline.

5. Future outlook

The company is currently operating under tight financial constraints. Their path forward relies on two main pillars: scaling the Nugevia brand to reach a break-even point and achieving clinical milestones for JOTROL™ to attract potential pharmaceutical partners. Without a significant increase in revenue or a breakthrough in their clinical trials, the company will likely need to raise additional capital through share offerings within the next 6 to 9 months.

Investor Takeaway: Jupiter Neurosciences is a high-risk, speculative investment. Because they are not yet profitable and face a "going concern" warning, your decision should weigh whether you believe their consumer brand (Nugevia) can generate enough cash to bridge the gap until their drug trials (JOTROL™) reach a point of commercial viability or partnership.